Show
Sort by
-
Standardized added metabolic activity (SAM) IN 18F-FDG PET assessment of treatment response in colorectal liver metastases
-
Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases
-
The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study
-
MDM2 gene amplification and protein expressions in colon carcinoma: is targeting MDM2 a new therapeutic option?
-
- Conference Paper
- C3
- open access
FDG-PET is a predictor of metabolic response to chemotherapy in metastatic colorectal cancer (mCRC)
-
- Conference Paper
- C3
- open access
Efficacy of the combined use of bevacizumab and irinotecan in a human colorectal cancer xenograft model analysed by SPECT imaging
-
- Conference Paper
- C3
- open access
PET as a predictor of metabolic response to antiangiogenic therapy in metastatic colorectal cancer (mCRC)
-
- Conference Paper
- C3
- open access
Preoperative chemotherapy for colorectal liver metastases : prediction of response by DCE-MRI abd FDG-PET/CT?
-
99mTc-(CO)3 His-annexin A5 micro-SPECT demonstrates increased cell death by irinotecan during the vascular normalization window caused by bevacizumab
-
- Miscellaneous
- open access
Assurance de qualité pour le cancer rectal : phase 3 : méthodes statistique visant à comparer les centres sur base d'un ensemble d'indicateurs de qualité